“We are pleased that the European Commission has approved the expanded use of Trelegy Ellipta as this will enable even more COPD patients to benefit from this important medicine,” Dr. Hal Barron, Chief Scientific Officer and President, R&D, GSK, said.
“We are pleased that the European Commission has approved the expanded use of Trelegy Ellipta as this will enable even more COPD patients to benefit from this important medicine,” Dr. Hal Barron, Chief Scientific Officer and President, R&D, GSK, said.